Whole Exome Sequencing Devices are Class 2
Federal Register notice: FDA is classifying whole exome sequencing devices into Class 2 (special controls). The move follows a 2019 request from Helix OpCo for the de novo classification of its Helix Learning Platform, which is used for analyzing the complete coding region of an individual’s DNA. The DNA sequence generated is intended as input for clinical germline DNA assays that have an FDA marketing authorization. To view the notice, click here.